Vir Biotechnology, Inc. Impairment of Intangible Assets (Excluding Goodwill)
Vir Biotechnology, Inc. (VIR) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-02-23
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2025-09-30 was $0.00.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2024-12-31 was $11.04M, a 300.07% increase year-over-year.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for the quarter ending 2024-09-30 was $0.00.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2024 was $14.55M, a 50.65% increase from fiscal 2023.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2023 was $9.66M.
- Vir Biotechnology, Inc. impairment of intangible assets (excluding goodwill) for fiscal 2022 was $0.00.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 3 month | Impairment of Intangible Assets (Excluding Goodwill) 6 month | Impairment of Intangible Assets (Excluding Goodwill) 9 month | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $11.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $11.04M derived: sum of 2 quarters · filed 2026-02-23 | $14.55M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.51M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $3.51M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $2.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.76M derived: sum of 2 quarters · filed 2026-02-23 | $9.66M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $6.90M 10-Q · filed 2024-11-04 | ||
| 2023-06-30 | $6.90M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $0.00 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-04 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-03-26 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |